Poor solubility is one of the most common challenges encountered during early-stage drug development. When an active pharmaceutical ingredient (API) does not dissolve adequately, it can limit bioavailability, affect dosing strategies, and hinder clinical progress. Overcoming these solubility challenges early ensures drug candidates move efficiently from preclinical research to First-in-Human (FiH) trials.
Key Takeaways
-
- Poor solubility can limit absorption, bioavailability, and therapeutic performance.
-
- Early solubility screening guides formulation decisions and development strategies.
-
- Approaches such as solid dispersions, nanotechnology, and lipid-based systems can overcome solubility challenges.
-
- Pre-formulation studies and analytical testing are critical for selecting the right solubility-enhancing approach.
-
- PharmSky offers complete formulation development and analytical solutions to support early-phase programs.
Why Solubility Matters in Drug Development
Up to 90% of drug candidates in development exhibit low aqueous solubility, making it difficult to achieve therapeutic levels in the body. Solubility directly affects dissolution rate, absorption, and ultimately bioavailability. For early-phase programs, inadequate solubility can prolong formulation development or result in inconclusive clinical outcomes.
At PharmSky, solubility assessments play a crucial role in Formulation Development and Analytical Services, ensuring that each compound’s properties are fully understood before determining the formulation strategy.
Common Causes of Poor Solubility
Several factors influence solubility, including the chemical nature of the API, its crystalline form, and intermolecular interactions. The most common causes of poor solubility include:
-
- Hydrophobic or lipophilic molecular structure: APIs with large nonpolar regions or high log P values often have limited solubility in aqueous environments.
-
- High molecular weight: This characteristic hinders dissolution and diffusion.
-
- Solid-state form: Crystalline (or polymorphic) vs. amorphous forms can significantly change solubility behaviour.
Understanding these characteristics early helps formulation scientists select the most suitable excipients and formulation techniques.
Techniques to Improve Drug Solubility
Solubilising techniques to improve solubility are selected based on the physicochemical properties of the drug substance.
1. Solid Dispersions
Solid dispersions enhance dissolution rates by dispersing the API within a hydrophilic carrier. This approach is particularly effective for poorly water soluble, thermally stable APIs.
2. Nanotechnology-Based Formulations
Nanoparticle formulations, such as nanoemulsions or solid lipid nanoparticles, significantly increase surface area and dissolution rate. PharmSky’s Nanotechnology Platform offers scalable nanotechnology solutions suitable for preclinical and clinical applications.
3. Lipid-Based Delivery Systems
For highly lipophilic drugs, self-emulsifying drug delivery systems (SEDDS) or lipid emulsions enhance solubility and promote absorption in the gastrointestinal tract.
4. Co-Solvent and Surfactant Systems
Solvents and surfactants reduce surface tension, improving drug wettability and dissolution. This is often applied in oral liquid and injectable formulations.
5. Cyclodextrin Complexation
Cyclodextrins form inclusion complexes that increase the apparent solubility of hydrophobic molecules while maintaining drug stability.
These approaches can be used individually or in combination as part of a tailored solubility enhancement strategy.
The Role of Pre-Formulation Studies
Pre-formulation studies evaluate solubility, stability, and compatibility before finalising the formulation design. These assessments provide critical data to determine:
-
- The most appropriate solvent systems.
-
- Excipient compatibility and impact on stability.
-
- The ideal formulation pathway (e.g., co-solvent, emulsion, or solid dispersion).
PharmSky implements the QbD approach for formulation development to ensure safe, efficacious and high quality products are developed.
Scaling from Laboratory to Clinical Trial Manufacturing
Once a solubility-enhancing strategy has been selected, scaling to clinical production must ensure the same dissolution and stability profile. This requires close coordination between formulation scientists, analytical teams, and manufacturing specialists.
PharmSky’s Clinical Trial Manufacturing team ensures consistent material quality across all batches, supporting preclinical through Phase I trials with GMP-compliant production.
Solving Solubility Early for Clinical Success
Solubility issues are among the leading causes of delays in early drug development. By addressing these challenges during the formulation stage, developers canreduce time to clinical readiness.
PharmSky’s integrated Formulation Development, Analytical Services, and Clinical Trial Manufacturing solutions provide the scientific and technical foundation to overcome solubility challenges effectively.
For tailored support in developing solubility-enhanced formulations, contact our team.
